ライフサイエンスコーパス: CD4 cell count

1 ection with detectable viremia regardless of CD4 cell count.

2 virological failure, and mean differences in CD4 cell count.

3 and to stimulate complete recovery of normal CD4 cell count.

4 infections in HIV-positive people with high CD4 cell count.

5 as, by contrast, independent of the mother's CD4 cell count.

6 , the Bio-Rad Avidity assay, viral load, and CD4 cell count.

7 ths are linked with continued improvement in CD4 cell count.

8 ssay (ELISA) in a fully automated manner for CD4 cell count.

9 y identical to that of the MAA that included CD4 cell count.

10 yone infected with HIV irrespective of their CD4 cell count.

11 intravenous drug use, geographic origin, and CD4 cell count.

12 ended antiretroviral therapy irrespective of CD4 cell count.

13 ity were disseminated tuberculosis and a low CD4 cell count.

14 quality of available data increase at lower CD4 cell counts.

15 re 0.944 for log(10) HIV-1 RNA and 0.840 for CD4 cell counts.

16 ations, such as opportunistic infections and CD4 cell counts.

17 infection, diabetes, alcohol abuse, and low CD4+ cell count.

18 lines recommend initiating ART regardless of CD4+ cell count.

19 ART initiation at diagnosis, irrespective of CD4(+) cell count.

20 In univariable analysis, higher time-updated CD4 cell count (0.78, 0.71-0.85, p=0.0001) was associate

21 lammation and viral load set point and blood CD4 cell counts 12 months after infection were investiga

22 d Hispanic patients had lower median initial CD4 cell count (132 cells/mm(3)) than documented Hispani

23 ed with human immunodeficiency virus (median CD4 cell count, 14 [IQR, 6-33] cells/microL).

24 pes; 44% women; median age, 35 years; median CD4 cell count, 151 cells/microL; median VL, 5.0 log10 c

25 up was 321 cells per muL higher, and average CD4 cell count 194 cells per muL higher than the deferre

26 , driven in part by hospitalization at lower CD4 cell counts; 2) for treatment changes, and 3) for ea

27 nificantly lower risk vs placebo of reaching CD4 cell count 250/muL or less (adjusted hazard ratio [H

28 e diagnostic algorithm (58.5% female; median CD4 cell count, 278/muL; WHO HIV stage I, 66.8%), 98 (10

29 ere randomly assigned (1:1) to point-of-care CD4 cell counts (366 compounds with 417 participants) or

30 stent plasma viremia of <200 copies/mL (mean CD4(+)-cell count, 475.1+/-307.9 cells/muL).

31 ction: 39 (45%) of 87 women with HIV and low CD4 cell counts, 52 (59%) of 88 women with HIV and high

32 Ninety-three HIV-infected children (median CD4 cell count, 655 cells/muL; plasma HIV RNA level, 4.7

33 risk is increased in association with a low CD4+ cell count (a clinical measurement of immune status

34 ociated with normalisation were high pre-ART CD4 cell counts, a high CD4/CD8 ratio at baseline, and n

35 ignificantly associated with a difference in CD4 cell count after 1 year of treatment.

36 The dramatic changes in viral load and CD4 cell count after therapy initiation highlight the ov

37 itted infections were also observed at lower CD4 cell counts after adjusting for age.

38 83, 95% CI 0.70-0.99; I(2)=51%, adjusted for CD4 cell count and ART duration), and there was some evi

39 Absolute CD4 cell count and CD4 cell percentage relationships wer

40 RT versus no cART, adjusted for time-varying CD4 cell count and HIV RNA level via inverse probability

41 that differ in the threshold used to measure CD4 cell count and HIV RNA viral load every 3-6 months (

42 ted for age, sex, race, cohort, time-updated CD4 cell count and HIV RNA were estimated in calendar pe

43 on of CD38 and HLA-DR surface markers), with CD4 cell count and HIV viral load as secondary outcomes.

44 fied by trial site and adjusted for maternal CD4 cell count and infant birth weight, indicated that n

45 study suggests that DAART, independently of CD4 cell count and risky behavior, has a potentially str

46 Factors associated with higher CD4 cell count and viral load (VL) suppression<400 c/mL

47 The joint distribution of CD4 cell count and viral load over time was depicted in

48 Still, the CD4 cell count and viral load represent the laboratory p

49 S using interactive provider alerts improved CD4 cell counts and clinic follow-up for patients with H

50 berculosis diagnosed had significantly lower CD4 cell counts and hemoglobin levels, more advanced WHO

51 s likely to be receiving cART, and had lower CD4 cell counts and higher viral loads.

52 Median baseline CD4 cell counts and HIV RNA concentrations did not diffe

53 e-specific polymerase chain reaction system; CD4 cell counts and HIV RNA were measured with flow cyto

54 ated cancer and determined by differences in CD4 cell counts and human immunodeficiency virus (HIV) R

55 Longitudinal CD4 cell counts and plasma viral load measurements befor

56 ening in HIV-infected patients with very low CD4 cell counts and provides important incremental yield

57 ng, infant feeding counselling, referral for CD4 cell counts and treatment, home-based services, anti

58 However, in settings where both CD4 cell counts and viral load testing are routinely ava

59 s of HIV disease severity represented by low CD4(+) cell count and high viral load, assessed by multi

60 time-updated clinical measurements including CD4(+) cell count and viral load with the outcome of inc

61 A subset of PLWHA who had a CD4(+) cell count and VL measurement near the time of th

62 Despite similar baseline CD4(+) cell counts and blood plasma viral loads, women w

63 ents who received Thymoglobulin showed lower CD4(+) cell counts and lower levels of IgM, at an averag

64 In the periphery, initial reduction of CD4(+) cell counts and their reconstitution on treatment

65 rveillance and registry databases, including CD4(+) cell counts and VL.

66 odel to analyze associations between pre-ART CD4+ cell counts and death, attrition, and death or attr

67 IV) patients has been associated with higher CD4+ cell counts and lower HIV-1 viral loads, with the u

68 IL-2 alone or with peri-cycle ART increased CD4+ cell counts (and so delayed initiation of ART) in H

69 is did not develop, matched by age, sex, and CD4 cell count, and 37 unmatched HIV-infected patients w

70 ning illness, a greater 12-month increase in CD4 cell count, and a smaller risk of virologic failure

71 were included; their median body mass index, CD4 cell count, and fat mtDNA level were 26 kg/m(2), 227

72 ecent calendar period, a higher contemporary CD4 cell count, and first-line regimens based on nonnucl

73 tion persisted after adjustment for age, the CD4 cell count, and HIV viral load at diagnosis.

74 oglobin level, albumin level, HIV infection, CD4 cell count, and HIV-1 RNA level.

75 fidence interval: 1.7, 3.2), reduced current CD4 cell count, and increased numbers of oral sex and "r

76 nel, and stratified by HIV-1 RNA viral load, CD4 cell count, and intention to use zidovudine, with th

77 wed for 5 years for HIV-1 plasma viral load, CD4 cell count, and mortality.

78 evaluate the association between HIV status, CD4 cell count, and other clinical predictors and antibo

79 f monitoring strategies, including clinical, CD4 cell count, and viral load monitoring, alone and tog

80 vent rates stratified by person-time in age, CD4 cell count, and VL and ARV categories.

81 and mortality among PHIVY stratified by age, CD4 cell count, and VL and ARV status.

82 rates and life expectancy stratified by sex, CD4 cell count, and WHO disease stage at enrolment in ca

83 unts, 52 (59%) of 88 women with HIV and high CD4 cell counts, and 60 (67%) of 90 women in the HIV-uni

84 nts without HIV, 89 and 88 with HIV and high CD4 cell counts, and 91 and 91 with HIV and low CD4 cell

85 smoking status) and was apparent across all CD4 cell count, antiretroviral therapy, and viral load s

86 age (AOR, 1.05; 95% CI, 1.03-1.08), and low CD4+ cell count (AOR, 2.36; 95% CI, 1.3-4.2).

87 However, the influence of CD4+ cell counts appeared to be strongest 6-7 years prio

88 Individuals with cirrhosis or low current CD4 cell count are at highest risk of developing HCC or

89 Human immunodeficiency virus infection and CD4 cell count are only 2 of many factors associated wit

90 active antiretroviral therapy and increased CD4 cell counts are associated with improved immune resp

91 fected individuals with relatively preserved CD4 cell counts are at higher risk for lower respiratory

92 Early ART initiation and maintenance of high CD4 cell counts are essential to further reducing KS inc

93 HIV-1 RNA and CD4 cell counts are important parameters for HIV care.

94 HIV disease markers, such as viral load and CD4 cell counts, are not strongly associated with ongoin

95 Logistic regression analysis included CD4(+) cell count as a covariate.

96 bacterial infections, and mortality at lower CD4 cell counts, as expected.

97 ses, loss of LTNP status was associated with CD4 cell count at 10 years after seroconversion (p < 0.0

98 The median CD4 cell count at baseline was 18 cells per muL (IQR 9-3

99 Median CD4 cell count at baseline was 339 cells/microL (interqu

100 ratified by plasma HIV-1 RNA viral loads and CD4 cell count at baseline.

101 achieved a suppressed HIV VL, and the median CD4 cell count at death.

102 s of antiretroviral therapy use, HIV VL, and CD4 cell count at death.

103 h pre-ART and ART stages included older age, CD4 cell count at initiation, and male sex.

104 Median CD4 cell count at lymphoma diagnosis among IRIS cases wa

105 ts from 169 007 patients in 44 studies, mean CD4 cell count at presentation increased minimally by 1.

106 hed January 2002-December 2013 that reported CD4 cell count at presentation or ART initiation among a

107 o generate an estimate of the time trend for CD4 cell count at the initiation of HIV care.

108 an-Meier estimator stratified by the initial CD4 cell count at the period of continuous suppression i

109 start of the Masa programme in 2002, average CD4 cell counts at enrolment increased (from 101 cells/m

110 In developed countries, patients' CD4 cell counts at first presentation to medical care ha

111 CD4 cell counts at HIV diagnosis are fundamental to the

112 ran Africa, contributing to persistently low CD4 cell counts at treatment initiation.

113 Across studies, the median CD4(+) cell count at ART initiation was 104 cells/mm(3),

114 is study suggest that HIV patients with high CD4+ cell counts at the time of ART initiation may be at

115 s than 400 copies per mL, and mean change in CD4 cell count, at weeks 156 and 240.

116 sex-treatment arm interaction, pretreatment CD4 cell count, baseline VL, and subtype, was still inde

117 cell count or re-present with persistent low CD4 cell counts because of poor adherence, resistance to

118 significantly increased with lower maternal CD4 cell count, before and after adjustment for maternal

119 partly explained by ART-induced increases in CD4 cell count, but not by increases in neutrophil count

120 a tended to be higher among those with lower CD4 cell counts, but did not predict death.

121 Geometric means were calculated for CD4 cell counts by month and calendar year.

122 Point-of-care CD4 cell counts can improve linkage to HIV care among pe

123 bing the number or proportion of patients in CD4 cell count categories.

124 munodeficiency virus (HIV)-1 RNA level (VL), CD4 cell counts (CD4), subtype, and treatment failure du

125 ime-updated lagged and cumulative exposures (CD4 cell count, CD8 cell count, CD4/CD8 ratio, HIV RNA,

126 use assays for BED, avidity, viral load, and CD4 cell count data from clade B samples collected in se

127 a or serum samples without a requirement for CD4 cell count data.

128 years, and applied mixed effects models for CD4 cell count decline and median regression for viral l

129 e, composition, turnover, HIV incidence, and CD4 cell count development.

130 CD4 cell counts did not influence the oral or BAL microb

131 9-1.73) for threshold 350, and 24 month mean CD4 cell count differences were 0.4 (-25.5 to 26.3) cell

132 ficant proportion of individuals with higher CD4 cell counts do not start ART within recommended time

133 f-care (318 compounds with 353 participants) CD4 cell counts done at one of three referral laboratori

134 for condomless sex, square-root-transformed CD4 cell count, drug use, and patient demographics.

135 However, changes in CD4 cell count during ART, which were similar between co

136 Viral load monitoring without CD4 cell count every 6-12 months provides the greatest r

137 We measured CD4 cell counts every 6 months and plasma HIV RNA annual

138 CD4 cell counts fell to <200 cells/microL in 5.7% of mon

139 CD4 cell counts fell to <200 cells/microL in 7.4% patien

140 y virus type 1 (HIV-1) plasma viral load and CD4 cell count for 5 years after antiretroviral therapy

141 antiretroviral therapy (ART) irrespective of CD4 cell count for all patients with tuberculosis who al

142 in HBsAg at months 6 and 12 correlated with CD4 cell count for HBeAg-positive patients.

143 ovember 2011 to identify those that reported CD4 cell count for patients newly presenting to HIV care

144 The median CD4 cell count for women with HIV was 397 (interquartile

145 ian CD4 cell count or reconstructed the mean CD4 cell count from the presented data describing the nu

146 After exclusion of CD4 cell counts from the model, higher HIV RNA load at 1

147 HIV RNA of less than 50 copies per mL and a CD4 cell count greater than 350 cells per muL.

148 patients infected with HIV subtype C with a CD4 cell count greater than 350/muL who were not receivi

149 positive patients with tuberculosis who have CD4 cell counts greater than 220 cells per muL.

150 to the vaccine (six [7%] in the HIV and low CD4 cell count group, 12 [13%] in the HIV and high CD4 c

151 ll count group, 12 [13%] in the HIV and high CD4 cell count group, and 21 [23%] in the HIV-uninfected

152 t <200 cells/microl compared to those with a CD4 cell count >/=200 cells/microl.

153 In the CD4 cell count >/=200 cells/mL stratum, MN GMTs were sig

154 ence was high even among patients with nadir CD4 cell count >200 cells/microL (140 per 100 000 person

155 ccal polysaccharide vaccine (PPSV23) and had CD4 cell counts >/= 200 cells/mm(3) and HIV viral loads

156 ted adults with prior PPSV23 vaccination and CD4 cell counts >/= 200 cells/mm(3).

157 In patients with CD4 cell counts >/=200 CD4 cells/muL, the most frequent

158 by estimating the probability of maintaining CD4 cell counts >/=200 cells/microL during continuous HI

159 al diseases are substantial in patients with CD4 cell counts >/=200 cells/muL.

160 Comparing patients with current CD4 cell counts >/=700 cells/microL with those whose cou

161 ted patients with suppressed viral loads and CD4 cell counts >300 cell/muL could be reduced to annual

162 d annually in HIV-monoinfected patients with CD4 cell counts >300 cells/microL and HIV/HCV-coinfected

163 ed risk of liver-related death compared with CD4 cell counts >350 cell/mm(3).

164 However, for patients with a CD4(+) cell count >500/microL, clinicians would defer AR

165 ion status (no infection, infection and high CD4 cell count [>350 cells per muL], and infection and l

166 [>350 cells per muL], and infection and low CD4 cell count [>50 to </=350 cells per muL]) and receiv

167 had a suppressed viral load and their median CD4 cell count had increased.

168 Adjusting for CD4 cell counts had no effect on decay estimates.

169 CD4 cell count has a complex relationship to Hodgkin lym

170 ere bacterial infections in people with high CD4 cell counts have not been well described.

171 ent HIV type 1 RNA level, lower pretreatment CD4 cell count, hepatitis C antibody, less education, an

172 After adjustment for age, CD4(+) cell count, hepatitis B or C virus infection, and

173 The risk of HZ was associated with low CD4 cell counts, high HIV RNA levels, low CD4/CD8 ratios

174 resents a treatment option for patients with CD4 cell counts higher than 200 cells per muL.

175 nical parameters, including body mass index, CD4 cell count, HIV load, and C-reactive protein levels

176 arms were well-balanced with respect to age, CD4 cell count, HIV RNA load, and antiretroviral treatme

177 orbidities, HIV status and related measures (CD4 cell counts, HIV viral load, and use of highly activ

178 Demographic and HIV variables (nadir/entry CD4(+) cell count, HIV RNA level, antiretroviral therapy

179 Higher baseline log10 CD4+ cell count (HR, 0.50; 95% CI, .40-.63) and increasi

180 vere bacterial infection in people with high CD4 cell counts in a preplanned analysis of the START tr

181 INTERPRETATION: Point-of-care CD4 cell counts in a resource-limited HBCT setting doubl

182 ssified as "HIV-related," with similarly low CD4 cell counts in both groups.

183 monitoring strategies based on time-varying CD4 cell counts in virologically suppressed HIV-positive

184 or both among HIV-infected adults with high CD4+ cell counts in Ivory Coast.

185 Mean CD4 cell count increase (analysed by an observed failure

186 ss than 400 copies per mL in 210 (45%); mean CD4 cell count increased by 183 cells per muL.

187 line regimen, and calendar year, low current CD4 cell counts increased the risk of developing KS thro

188 emtricitabine, and efavirenz) regardless of CD4 cell count (intervention) or according to national g

189 The micro-a-fluidic CD4 cell count is achieved by eliminating operational fl

190 Whereas soon after starting cART low CD4 cell count is the dominant risk factor, detectable H

191 After adjustment for age, CD4 cell counts, last HIV viral load, antiretroviral the

192 0 weeks for post-48-week switch at the first CD4 cell count less than 100 cells/mm(3) or non-Candida

193 an increased risk of HFrEF, and time-updated CD4 cell count less than 200 cells/mm3 compared with at

194 Reaching a CD4 cell count less than 200/muL until May 2008; after t

195 cogenic HPV-negative HIV-infected women with CD4 cell count less than 350 cells/muL (cumulative incid

196 ults (aged >/=18 years) living with HIV with CD4 cell count less than or equal to 350 cells per muL w

197 ohort study to assess the effects of pre-ART CD4+ cell count levels on death, attrition, and death or

198 mes for HIV-positive people were obtaining a CD4 cell count, linkage to an HIV clinic, ART initiation

199 antiretroviral therapy coverage, firstly at CD4 cell count lower than 350 cells per muL, and then at

200 lower than 350 cells per muL, and then at a CD4 cell count lower than 500 cells per muL, using lower

201 f combined outcomes for disease progression (CD4 cell count </=250/muL, AIDS-defining conditions, or

202 and MsgC9 among HIV-positive patients with a CD4 cell count <200 cells/microl compared to those with

203 ies/mL; 5% and 18% vs 2% of person-time with CD4 cell count <200/microL; P < .001 for each comparison

204 nt, before and after adjustment for maternal CD4 cell count <350 and 350-499 CD4/mm(3) (adjusted haza

205 adults (aged >/=21 years) with advanced HIV (CD4 cell counts </=125 cells per muL) and pulmonary tube

206 ART initiation for HIV-positive persons with CD4 cell counts </=500 cells/microL, a higher threshold

207 Furthermore, among HIV-infected subjects, CD4 cell counts <200 cells/mm(3) were associated with a

208 R at initiation of ART (P <.05) and 12-month CD4 cell counts <200 cells/muL (P <.05) were associated

209 , in hospitalized HIV-infected patients with CD4 cell counts <350/microL and microbiologically proved

210 iveness of four strategies for patients with CD4 cell-counts <100 cells/microl starting ART 1) no scr

211 ividuals aged 18-64 years were stratified by CD4 cell count (<200 cells/mL or >/=200 cells/mL) and ra

212 trata of age (7-12, 13-17, and 18-30 years), CD4 cell count (<200, 200-499, and >/=500/muL), and a co

213 stment for traditional risk factors, a lower CD4(+) cell count (<200 compared with >350 cells/mm(3);

214 At pretreatment, lower CD4 cell count, major resistance, more amino acid mixtur

215 A total of 5,083 (87.8%) having at least one CD4 cell count measure were included from 2005 to 2013.

216 gression of 197 point estimates encompassing CD4 cell count measurements from 169 007 patients in 44

217 For more than two decades, CD4 cell count measurements have been central to underst

218 ] vs 32 of 362 [8.8%]) and had lower current CD4 cell counts (median, 230 vs 383 cells/microL), lipid

219 ance rates (11% vs 30%; P = .003) and higher CD4(+) cell counts (median, 275 vs 213 cells/microL; P =

220 developing countries, simple and affordable CD4 cell counting methods are urgently needed in resourc

221 ted settings in the near term, point of care CD4 cell counts might have a role in prioritising care a

222 ected adults, irrespective of ART status and CD4 cell count, might be warranted.

223 From our data, it can be inferred that CD4 cell count monitoring can be safely performed annual

224 Regular CD4 cell count monitoring confers a benefit over clinica

225 We determined whether CD4 cell count monitoring could be reduced in monoinfect

226 It has been suggested that routine CD4 cell count monitoring in human immunodeficiency viru

227 ut evidence supporting similar reductions in CD4 cell count monitoring is lacking for this population

228 Log(10) HIV-1 RNA and CD4 cell count monthly means were also examined with pol

229 The main exposure variable was maternal CD4 cell count near delivery.

230 Of patients with a CD4 cell count of 220-349 cells per muL, 26 (7.9%) of 33

231 with recently diagnosed HIV infection and a CD4 cell count of 225/mm(3) began treatment with atazana

232 until May 2008; after this date, reaching a CD4 cell count of 250/muL or less, consistent with the s

233 Of monoinfected patients with an initial CD4 cell count of 300-349 cells/microL, 95.6% maintained

234 2% [95% CI, 0%-7%]), 1 case in 47 women with CD4 cell count of 350 to 499 cells/muL (cumulative incid

235 a median age of 39 years (33-45), and median CD4 cell count of 441 cells per mm(3) (294-628).

236 % CI, 0%-7%]), and 7 cases in 128 women with CD4 cell count of 500 cells/muL or greater (cumulative i

237 of 6.0% (95% CI 5.8-6.2) among people with a CD4 cell count of less than 100 cells per muL, with 278

238 ith a VL of 400 copies/mL or more and with a CD4 cell count of less than 200/microL compared with 7-

239 d their clients to meet WHO eligibility of a CD4 cell count of less than 500 cells per muL could aver

240 rial in ART-naive HIV-positive patients with CD4 cell count of more than 500 cells per muL assigned t

241 Eligible participants had CD4 cell counts of >/=500 cells/microL and were not taki

242 Time to treatment in men with CD4 cell counts of 250 cells per muL or fewer was lower

243 of HIV-1, HSV-2 dually infected adults with CD4 cell counts of 300-400 cells per muL.

244 on cART (viral load <50 copies per mL) with CD4 cell counts of 400 x 10(6) cells per L or greater.

245 Individuals enrolling in care with CD4 cell counts of 500 cells per muL or more, and with W

246 greater than 1000 HIV RNA copies per mL and CD4 cell counts of fewer than 500 cells per muL, except

247 ients initiating antiretroviral therapy with CD4 cell counts of less than 50 cells per muL.

248 stment for latest HIV RNA level, but not for CD4 cell count or cancer risk factors, attenuated the ef

249 e with advanced HIV infection and with a low CD4 cell count or re-present with persistent low CD4 cel

250 We abstracted the mean or median CD4 cell count or reconstructed the mean CD4 cell count

251 nal CMV viruria was not associated with mean CD4 cell counts or HIV viral load but was associated wit

252 es should consider reducing the frequency of CD4 cell counts or not doing routine CD4 monitoring for

253 breastfeeding women who started ART with low CD4 cell counts or World Health Organization clinical st

254 significantly influenced by HIV RNA levels, CD4+ cell counts, or antiretroviral therapy.

255 We estimated the change in CD4 cell count over time by modeling it as a weighted li

256 e intent ( P = .003), and those with a lower CD4 cell count ( P = .036).

257 Higher nadir CD4 cell count (P = .01) and plasma HIV RNA <50 copies/m

258 ted with higher viral load (P = .004), lower CD4 cell count (P = .01), and increased mortality (hazar

259 risk of lung cancer was associated with low CD4 cell count (p trend=0.001), low CD4/CD8 ratio (p tre

260 Patients with T0 KS had higher CD4 cell counts (P < .001); 90% of patients with T0 KS w

261 notype, antiretroviral regimen, HCV subtype, CD4 cell count, previous response to HCV treatment, HCV

262 rum lipid levels, HIV replication, low nadir CD4(+) cell count, protease inhibitor use, comorbid cond

263 started before or with ART, irrespective of CD4 cell count, reduces morbidity and mortality with ben

264 PrEP-treated macaques showed no significant CD4 cell count reduction during acute infection and deve

265 However, the median CD4 cell count remained below normal levels throughout f

266 HIV-RNA levels remained controlled and CD4 cell counts remained stable in all patients througho

267 cell counts, and 91 and 91 with HIV and low CD4 cell counts, respectively).

268 t was in those not infected, irrespective of CD4 cell count, resulting in lower levels of serotype-sp

269 disappeared after adjustment for the current CD4 cell count (RR, 1.03; 95% CI, .81-1.32).

270 Baseline weight, CD4 cell count status, and hemoglobin level were strongl

271 ity compared with uninfected patients at all CD4 cell count strata (>/=500/muL: IRR, 1.92; 95% CI, 1.

272 association between current HIV DNA load and CD4 cell counts suggests that the unique physiological c

273 delines now recommend limited use of routine CD4 cell count testing in human immunodeficiency virus (

274 sease staging with referral laboratory-based CD4 cell count testing is a key barrier to the initiatio

275 eferral, and then (1:1) either point-of-care CD4 cell count testing or referral for CD4 testing.

276 f front-line health workers, a point-of-care CD4 cell count testing platform, a revised counselling a

277 ng with counsellor support and point-of-care CD4 cell count testing would increase uptake of ART and

278 in multivariable analysis, particularly the CD4 cell count, the HR for immediate-initiation group mo

279 formula to compare 10-year mortality under 3 CD4 cell count thresholds for therapy initiation among 3

280 tform holds great promise for offering rapid CD4 cell count to scale up much needed ART in resource-c

281 h human immunodeficiency virus regardless of CD4 cell count under actual clinical conditions.

282 emia categories, accounting for time-varying CD4 cell count using marginal structural models.

283 ed information about the association of age, CD4 cell count, viral load (VL), and antiretroviral (ARV

284 ), and 81.6% were HIV infected; their median CD4 cell count was 47 cells/mul.

285 CD4 cell count was inversely associated with mortality,

286 During follow-up, CD4 cell count was measured on average every 4.0 months

287 In multivariable analysis, baseline CD4(+) cell count was significantly associated with 96-w

288 The median CD4(+)cell count was 612/muL, and the HIV load was <50 c

289 or factors that changed over time, including CD4 cell count, we detected no decreases in AIDS-related

290 Median baseline pVL and CD4 cell count were 9544 copies/mL (inter quartile range

291 Older age, cirrhosis, and low current CD4 cell count were associated with a higher incidence o

292 ed improvements in HIV-1 RNA suppression and CD4 cell counts were achieved in a large inner-city popu

293 ned to immediate ART or deferral until their CD4 cell counts were lower than 350 cells per muL.

294 CD4 cell counts were measured every 12 weeks in both gro

295 iation, particularly among patients with low CD4 cell counts, whereas other cancers increased with ti

296 CI: 4.64, infinity) of HPV16, as well as low CD4+ cell counts, whether measured at nadir (OR per 100-

297 CD4 cell counts will continue to play an important part

298 ed with higher IL-6 levels, and higher nadir CD4(+) cell counts with lower IL-6 levels.

299 s the overall trends in HIV-1 viral load and CD4 cell counts within our clinic.

300 uals remain AIDS-free with a high and stable CD4 cell count without antiretroviral therapy (ART) for